Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Payables (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Payables for 11 consecutive years, with $20.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Payables rose 38.82% to $20.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $20.3 million, a 38.82% increase, with the full-year FY2025 number at $20.3 million, up 38.82% from a year prior.
  • Payables was $20.3 million for Q4 2025 at Intellia Therapeutics, up from $13.3 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $20.3 million in Q4 2025 to a low of $3.6 million in Q3 2023.
  • A 5-year average of $10.3 million and a median of $9.7 million in 2021 define the central range for Payables.
  • Peak YoY movement for Payables: soared 97814.29% in 2021, then tumbled 47.91% in 2025.
  • Intellia Therapeutics' Payables stood at $9.7 million in 2021, then crashed by 46.61% to $5.2 million in 2022, then surged by 44.59% to $7.5 million in 2023, then skyrocketed by 95.77% to $14.6 million in 2024, then soared by 38.82% to $20.3 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Payables are $20.3 million (Q4 2025), $13.3 million (Q3 2025), and $9.8 million (Q2 2025).